BioCentury | Nov 21, 2020

Mei readies Antengene to take its next steps to becoming a global biotech

Fresh off its $360 million IPO on the Hong Kong stock exchange, Shanghai’s Antengene is looking to take the next step in its evolution by building out its pipeline and launching its first drug....
BioCentury | Oct 3, 2020
Management Tracks

Li to guide Merck’s next wave of cancer therapies launched by Perlmutter

Dean Li will take over a Merck Research Laboratories that has been transformed by Roger Perlmutter over the past seven years, guiding a pharma that had been struggling with a patent cliff to the company...
BioCentury | Sep 18, 2020
Management Tracks

Former AZ CMO Bohen brings his cancer chops to Olema

Two months after closing a $54 million series B round, breast cancer company Olema has followed up a flurry of executive hires with the addition of former AstraZeneca CMO Sean Bohen as president and CEO. ...
BioCentury | Sep 4, 2020
Product Development

Akebia’s prospects dim after safety readout in non-dialysis CKD patients

The failure of Akebia’s vadadustat on a Phase III safety endpoint in a subset of chronic kidney disease patients won’t stop the company from submitting the molecule to regulators. But the readout surprised...
BioCentury | Jul 21, 2020
Product Development

Data Bytes: COVID-19 pipeline still growing

Last week saw at least 17 new programs added to the COVID-19 pipeline, bringing the total number of candidates BioCentury is tracking in its COVID-19 Resource Center to 679. Among the 12 new therapeutic entrants...
BioCentury | Jun 30, 2020

Data Bytes: Drug approvals in Japan

On Monday, Japan’s Ministry of Health, Labour and Welfare announced at least nine drug approvals, five of which are products from Novartis AG (NYSE:NVS; SIX:NOVN). Two of the approvals are for HIF-PH inhibitors to treat...
BioCentury | Jun 25, 2020
Emerging Company Profile

Simcha launches with $25M WuXi-led series A, new take on IL-18 for cancer

Simcha emerged Wednesday with $25 million in series A funding to bring its lead product, a variant of IL-18 designed to thwart a resistance mechanism in tumors, through Phase I testing. The corporate venture fund...
BioCentury | Jun 19, 2020
Politics, Policy & Law

Juneteenth and our path forward: Letter from BioCentury’s Co-Founders

Editor’s Note: BioCentury’s co-founders, Chairman Karen Bernstein, Ph.D., and President & CEO David Flores, have written to the company’s employees about BioCentury’s response to racism and racial inequities in healthcare. It is published in its...
BioCentury | May 29, 2020
Distillery Therapeutics

Epigenetic protein PHF20L1 identified as breast cancer target

DISEASE CATEGORY: Cancer INDICATION: Breast cancer Inhibiting PHF20L1, an epigenetic protein that recognizes methylated histone residues, could treat breast cancer. In breast cancer patients, high tumor levels of PHF20L1 protein were associated with high histological...
BioCentury | May 16, 2020
Politics, Policy & Law

New BIO leader McMurry-Heath to focus on patients and innovation

BIO is looking to its new CEO and President, Michelle McMurry-Heath, to serve as a new face and voice for the industry, and to refocus the organization on patients and on creating the innovations they...
Items per page:
1 - 10 of 483